RNA-binding proteins as important regulators of long non-coding RNAs in cancer
- Sprache
-
Englisch
- Identifier
-
1280804467
- Beteiligte Personen und Organisationen
- DOI
-
10.3390/ijms21082969
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
02.05.2023, 09:12 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jonas, Katharina
- Calin, George A.
- Pichler, Martin
Ähnliche Objekte (12)
Best of ASCO 2022: bladder cancer
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Inflammation, phagocytosis and cancer: another step in the CD47 act
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
The role of microRNAs in breast cancer stem cells
Multi-omics in prognosis of hepatocellular carcinoma
Non-coding RNAs and SARS-related coronaviruses
Best of ASCO 2022: bladder cancer
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Inflammation, phagocytosis and cancer: another step in the CD47 act
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
The role of microRNAs in breast cancer stem cells
Multi-omics in prognosis of hepatocellular carcinoma
Non-coding RNAs and SARS-related coronaviruses
Best of ASCO 2022: bladder cancer
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Inflammation, phagocytosis and cancer: another step in the CD47 act
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
The role of microRNAs in breast cancer stem cells
Multi-omics in prognosis of hepatocellular carcinoma